As the largest resource of information specific to women's brain health, we are sure you will find what you are looking for, and promise that you will discover new information.
Published on: February 18, 2015
by Neurology Advisor:
Researchers from Sweden may have uncovered a link between Alzheimer’s and type 2 diabetes through research on amyloidosis, backing up research that claims patients with type 2 diabetes have a near two-fold greater risk of developing Alzheimer’s disease.
The formation of fibril deposits occurs in both Alzheimer’s and type 2 diabetes (T2D), however new research suggests that amyloid formation in the brain may stimulate the growth of fibrils in the murine pancreas. Additionally, pancreatic-related amyloid can be found along human brain senile plaques.
Focusing on how amyloid deposits spread within a tissue or from organ to organ, researchers injected transgenic mice that expressed humam islet amyloid polypeptide (IAPP) with preformed fibrils of synthetic IAPP, proIAPP, or beta-amyloid. After 10 months, the number of islets with amyloid was significantly higher compared to controls of all three types of fibrils. Additionally, the amyloid consisted of IAPP across all groups, and no amyloid deposits were found in the spleen, kidney, liver, heart, or lungs.
Researchers then analyzed human tissue from the pancreas and brain, and found that sections of pancreas with islet amyloid in patients with T2D had no beta-amyloid immunoreactivity, while all samples were immunoreactive for IAPP. Researchers also analyzed samples of the temporal cortex from patients with Alzheimer’s and compared them to patients with frontotemporal dementia, progressive supranuclear palsy, or no neurologic disease. IAPP reactivity was found in all samples, and those from Alzheimer’s patients had 1.4 times higher concentrations of IAPP than non-Alzheimer’s patients.
While researchers aren’t yet clear on how or if IAPP is produced or derived from pancreatic beta-cells, cross-seeding by amyloid aggregates may be a possible mechanism for the initiation of amyloid formation.
Thirty-six million people worldwide suffer from Alzheimer’s disease and dementia. In Canada, 25,000 new cases are diagnosed each year. Those sobering numbers have researchers around the globe racing to come up with new ways to...
he Food and Drug Administration issued new guides on drug development for neurological disorders. This sets the stage for possible treatments for Alzheimer’s. The disease-oriented development guide documents will provide details on how researchers...
For young adults with autosomal dominant Alzheimer’s disease (AD), molecular markers can identify changes associated with the disease before clinical onset, according to a study published online Feb. 12 in JAMA Neurology. Yakeel T. Quiroz, Ph.D., from Massachusetts...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.